Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Barbie

Showing results (11-20 of 120) with videos related to

Pageof 12
Sort By:
Pharmacogenomics|October 11, 2014
Targeting pathways downstream of KRAS in lung adenocarcinomaZehua Zhu, Hadrien G Golay, David A Barbie
Trends in Cell Biology|June 7, 2005
Nuclear tumor suppressors in space and timeDavid A Barbie, Lindus A Conlan, Brian K Kennedy
Journal of Clinical Gastroenterology|October 20, 2004
Eosinophilic gastroenteritis associated with systemic lupus erythematosusDavid A Barbie, Abeel A Mangi, Gregory Y Lauwers
British Journal of Cancer|January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitorsRussell W Jenkins, David A Barbie, Keith T Flaherty
Cancers|December 9, 2023
Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung CancerMaria Saigí, Oscar Mesía-Carbonell, David A Barbie, et al.
Current Opinion in Molecular Therapeutics|June 4, 2010
Functional genomics and cancer drug target discoverySusan E Moody, Jesse S Boehm, David A Barbie, et al.
Cancer Cell|December 25, 2025
Targeting STING to generate therapeutic anti-tumor immunityCaroline G Fahey, Anthony F Cordova, Patrick C Gedeon, et al.
Iscience|January 25, 2021
Engineering approaches for studying immune-tumor cell interactions and immunotherapySarah E Shelton, Huu Tuan Nguyen, David A Barbie, et al.
Annual Review of Medicine|November 4, 2017
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerRussell W Jenkins, Rohit Thummalapalli, Jacob Carter, et al.
Expert Opinion on Therapeutic Targets|March 11, 2021
KRAS G12C inhibition and innate immune targetingTetsuo Tani, Shunsuke Kitajima, Ella B Conway, et al.
Pageof 12

Showing results (11-20 of 120) with videos related to

Sort By:
Pageof 12
Pharmacogenomics|October 11, 2014
Targeting pathways downstream of KRAS in lung adenocarcinomaZehua Zhu, Hadrien G Golay, David A Barbie
Trends in Cell Biology|June 7, 2005
Nuclear tumor suppressors in space and timeDavid A Barbie, Lindus A Conlan, Brian K Kennedy
Journal of Clinical Gastroenterology|October 20, 2004
Eosinophilic gastroenteritis associated with systemic lupus erythematosusDavid A Barbie, Abeel A Mangi, Gregory Y Lauwers
British Journal of Cancer|January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitorsRussell W Jenkins, David A Barbie, Keith T Flaherty
Cancers|December 9, 2023
Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung CancerMaria Saigí, Oscar Mesía-Carbonell, David A Barbie, et al.
Current Opinion in Molecular Therapeutics|June 4, 2010
Functional genomics and cancer drug target discoverySusan E Moody, Jesse S Boehm, David A Barbie, et al.
Cancer Cell|December 25, 2025
Targeting STING to generate therapeutic anti-tumor immunityCaroline G Fahey, Anthony F Cordova, Patrick C Gedeon, et al.
Iscience|January 25, 2021
Engineering approaches for studying immune-tumor cell interactions and immunotherapySarah E Shelton, Huu Tuan Nguyen, David A Barbie, et al.
Annual Review of Medicine|November 4, 2017
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerRussell W Jenkins, Rohit Thummalapalli, Jacob Carter, et al.
Expert Opinion on Therapeutic Targets|March 11, 2021
KRAS G12C inhibition and innate immune targetingTetsuo Tani, Shunsuke Kitajima, Ella B Conway, et al.
Pageof 12